Lead Independent Director, Histogen, Inc.; Chairman, Phoenix Molecular Designs; Independent Director, Paracrine Inc.; Director, California Life Sciences; Chair of Capital Development and Board of Governors, BIOCOM California; Managing General Partner, Equitos Venture Partners LLC

David H. Crean

David has +25 years buy- and sell-side expertise of M&A, partnering and investments within the life sciences and healthcare sectors working within strategic biopharmaceutical companies, private equity, investment banking and venture capital. He is the Managing General Partner of Equitos Venture Partners LLC, an emerging life sciences-focused investment fund. In parallel to Equitos, he is a limited partner for Suncoast Ventures and Mesa Verde Venture Partners, two life sciences venture funds focused on incubator through growth-stage companies. Aside from his investment activities, he also serves as Managing General Partner for Cardiff Advisory LLC, a boutique mergers & acquisitions investment banking and strategic advisory firm focused on M&A for life sciences and healthcare companies. Through his Cardiff Advisory affiliation, he serves in fractional CEO and CBO roles for a few private and public companies.

David currently serves in leading Boards of Director roles for Histogen, Inc. (Nasdaq: HSTO) as Lead Independent Director, Phoenix Molecular Designs as Board Chairman, Independent Board Member for Paracrine Inc., on the Executive Committee and Board for California Life Sciences (CLS), and BIOCOM California’s Board of Governors as Chair of Capital Development. David is an active member of the Association for Corporate Growth (ACG) and served as President for the past two years of the San Diego, CA chapter, is active member of CEO’s Against Cancer for the American Cancer Society, and serves as Chairman of the Board for the Alzheimer’s Association for San Diego/ Imperial Counties.

David holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC. He holds a Doctorate of Philosophy (Ph.D.) Degree in Biophysics and a Masters of Science (MS) Degree in Oncology from the State University of New York at Buffalo. He earned a Bachelor of Science (BS) Degree in Biology/ Pre-Med from Canisius College. Additionally, he holds a Masters of Business Administration (MBA) Degree with a finance concentration from Pepperdine University Graziadio School of Management.

Vice President, Investor Relations, NuVasive, Inc.

Juliet Cunningham

Juliet Cunningham has been an investor relations professional for 25 years. She draws from a diverse background including corporate, financial, media and regulatory communications. Ms. Cunningham has served in senior IR and communications roles in healthcare (NuVasive, Nevro and Alere) and technology sectors (Qualcomm, Novatel Wireless and Linkabit Corp). In addition, she has consulted with companies ranging from start-ups to Fortune 500 in wireless technology, healthcare, and biotech. Ms. Cunningham has taken companies public, supported small and large M&A transactions, and has guided management teams through periods of transformative change. Juliet Cunningham holds a bachelor’s degree in business administration, and completed graduate programs in investor relations and executive leadership at the University of Michigan and Stanford University, respectively.

Senior Managing Director, Equity, Derivatives, and Quantitative Strategy Team, Evercore ISI

Julian Emanuel

Julian Emanuel is a Senior Managing Director leading the Equity, Derivatives, and Quantitative Strategy team at Evercore ISI.

Mr. Emanuel was Chief Equity and Derivatives Strategist at BTIG for the past four years with supplemental responsibility for Alternative Assets and Cryptocurrency Strategy. Prior roles include Chief U.S. Equity and Derivatives Strategist at UBS, as well as Portfolio Management responsibilities at Tiedemann Investment Group, Goldman Sachs/SLK, and Credit Suisse Asset Management. His unique background includes tenure as an Index and Single Stock options market maker on the American Stock Exchange and as Head of the Equity Derivatives sales desk at Tullett Prebon.

Mr. Emanuel holds an MBA in Finance from NYU’s Stern School of Business and a BBA from Emory University.